APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tourette Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Tourette Syndrome Drug Industry Research Report 2026

22 December 2025124 pages

Choose your research edition.

Industry ResearchTourette Syndrome Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Tourette Syndrome Drug Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Tourette Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tourette Syndrome Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Tourette Syndrome Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Tourette Syndrome Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Tourette Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Tourette Syndrome Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Tourette Syndrome Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Tourette Syndrome Drug include Teva Pharmaceutical Industries Ltd, Therapix Biosciences Ltd, Synchroneuron Inc, Reviva Pharmaceuticals Inc, Psyadon Pharmaceuticals Inc, Neurocrine Biosciences Inc, Catalyst Pharmaceuticals Inc and Abide Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Tourette Syndrome Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Tourette Syndrome Drug Market by Company

Teva Pharmaceutical Industries Ltd

Therapix Biosciences Ltd

Synchroneuron Inc

Reviva Pharmaceuticals Inc

Psyadon Pharmaceuticals Inc

Neurocrine Biosciences Inc

Catalyst Pharmaceuticals Inc

Abide Therapeutics Inc

Tourette Syndrome Drug Segment by Type

Ecopipam Hydrochloride

Dutetrabenazine ER

CPP-115

AZD-5213

Others

Tourette Syndrome Drug Segment by Application

Clinic

Hospital

Research Center

Others

Tourette Syndrome Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tourette Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tourette Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tourette Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Tourette Syndrome Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Tourette Syndrome Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Tourette Syndrome Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Tourette Syndrome Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Tourette Syndrome Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Tourette Syndrome Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Tourette Syndrome Drug Revenue of Manufacturers (2021-2026) Table 9. Global Tourette Syndrome Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Tourette Syndrome Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Tourette Syndrome Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Tourette Syndrome Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Tourette Syndrome Drug, Product Type & Application Table 14. Global Tourette Syndrome Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Tourette Syndrome Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Teva Pharmaceutical Industries Ltd Company Information Table 19. Teva Pharmaceutical Industries Ltd Business Overview Table 20. Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Product Portfolio Table 22. Teva Pharmaceutical Industries Ltd Recent Developments Table 23. Therapix Biosciences Ltd Company Information Table 24. Therapix Biosciences Ltd Business Overview Table 25. Therapix Biosciences Ltd Tourette Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Therapix Biosciences Ltd Tourette Syndrome Drug Product Portfolio Table 27. Therapix Biosciences Ltd Recent Developments Table 28. Synchroneuron Inc Company Information Table 29. Synchroneuron Inc Business Overview Table 30. Synchroneuron Inc Tourette Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Synchroneuron Inc Tourette Syndrome Drug Product Portfolio Table 32. Synchroneuron Inc Recent Developments Table 33. Reviva Pharmaceuticals Inc Company Information Table 34. Reviva Pharmaceuticals Inc Business Overview Table 35. Reviva Pharmaceuticals Inc Tourette Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Reviva Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio Table 37. Reviva Pharmaceuticals Inc Recent Developments Table 38. Psyadon Pharmaceuticals Inc Company Information Table 39. Psyadon Pharmaceuticals Inc Business Overview Table 40. Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio Table 42. Psyadon Pharmaceuticals Inc Recent Developments Table 43. Neurocrine Biosciences Inc Company Information Table 44. Neurocrine Biosciences Inc Business Overview Table 45. Neurocrine Biosciences Inc Tourette Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Neurocrine Biosciences Inc Tourette Syndrome Drug Product Portfolio Table 47. Neurocrine Biosciences Inc Recent Developments Table 48. Catalyst Pharmaceuticals Inc Company Information Table 49. Catalyst Pharmaceuticals Inc Business Overview Table 50. Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio Table 52. Catalyst Pharmaceuticals Inc Recent Developments Table 53. Abide Therapeutics Inc Company Information Table 54. Abide Therapeutics Inc Business Overview Table 55. Abide Therapeutics Inc Tourette Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Abide Therapeutics Inc Tourette Syndrome Drug Product Portfolio Table 57. Abide Therapeutics Inc Recent Developments Table 58. Global Tourette Syndrome Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 59. Global Tourette Syndrome Drug Sales by Region (2021-2026) & (k units) Table 60. Global Tourette Syndrome Drug Sales Market Share by Region (2021-2026) Table 61. Global Tourette Syndrome Drug Sales by Region (2027-2032) & (k units) Table 62. Global Tourette Syndrome Drug Sales Market Share by Region (2027-2032) Table 63. Global Tourette Syndrome Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Tourette Syndrome Drug Revenue Market Share by Region (2021-2026) Table 65. Global Tourette Syndrome Drug Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Tourette Syndrome Drug Revenue Market Share by Region (2027-2032) Table 67. North America Tourette Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. North America Tourette Syndrome Drug Sales by Country (2021-2026) & (k units) Table 69. North America Tourette Syndrome Drug Sales by Country (2027-2032) & (k units) Table 70. North America Tourette Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 71. North America Tourette Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 72. Europe Tourette Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. Europe Tourette Syndrome Drug Sales by Country (2021-2026) & (k units) Table 74. Europe Tourette Syndrome Drug Sales by Country (2027-2032) & (k units) Table 75. Europe Tourette Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 76. Europe Tourette Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 77. Asia Pacific Tourette Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Asia Pacific Tourette Syndrome Drug Sales by Country (2021-2026) & (k units) Table 79. Asia Pacific Tourette Syndrome Drug Sales by Country (2027-2032) & (k units) Table 80. Asia Pacific Tourette Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 81. Asia Pacific Tourette Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 82. South America Tourette Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. South America Tourette Syndrome Drug Sales by Country (2021-2026) & (k units) Table 84. South America Tourette Syndrome Drug Sales by Country (2027-2032) & (k units) Table 85. South America Tourette Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 86. South America Tourette Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 87. Middle East and Africa Tourette Syndrome Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Middle East and Africa Tourette Syndrome Drug Sales by Country (2021-2026) & (k units) Table 89. Middle East and Africa Tourette Syndrome Drug Sales by Country (2027-2032) & (k units) Table 90. Middle East and Africa Tourette Syndrome Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. Middle East and Africa Tourette Syndrome Drug Revenue by Country (2027-2032) & (US$ Million) Table 92. Global Tourette Syndrome Drug Sales by Type (2021-2026) & (k units) Table 93. Global Tourette Syndrome Drug Sales by Type (2027-2032) & (k units) Table 94. Global Tourette Syndrome Drug Sales Market Share by Type (2021-2026) Table 95. Global Tourette Syndrome Drug Sales Market Share by Type (2027-2032) Table 96. Global Tourette Syndrome Drug Revenue by Type (2021-2026) & (US$ Million) Table 97. Global Tourette Syndrome Drug Revenue by Type (2027-2032) & (US$ Million) Table 98. Global Tourette Syndrome Drug Revenue Market Share by Type (2021-2026) Table 99. Global Tourette Syndrome Drug Revenue Market Share by Type (2027-2032) Table 100. Global Tourette Syndrome Drug Price by Type (2021-2026) & (US$/unit) Table 101. Global Tourette Syndrome Drug Price by Type (2027-2032) & (US$/unit) Table 102. Global Tourette Syndrome Drug Sales by Application (2021-2026) & (k units) Table 103. Global Tourette Syndrome Drug Sales by Application (2027-2032) & (k units) Table 104. Global Tourette Syndrome Drug Sales Market Share by Application (2021-2026) Table 105. Global Tourette Syndrome Drug Sales Market Share by Application (2027-2032) Table 106. Global Tourette Syndrome Drug Revenue by Application (2021-2026) & (US$ Million) Table 107. Global Tourette Syndrome Drug Revenue by Application (2027-2032) & (US$ Million) Table 108. Global Tourette Syndrome Drug Revenue Market Share by Application (2021-2026) Table 109. Global Tourette Syndrome Drug Revenue Market Share by Application (2027-2032) Table 110. Global Tourette Syndrome Drug Price by Application (2021-2026) & (US$/unit) Table 111. Global Tourette Syndrome Drug Price by Application (2027-2032) & (US$/unit) Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Tourette Syndrome Drug Distributors List Table 115. Tourette Syndrome Drug Customers List Table 116. Tourette Syndrome Drug Industry Trends Table 117. Tourette Syndrome Drug Industry Drivers Table 118. Tourette Syndrome Drug Industry Restraints Table 119. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Tourette Syndrome Drug Product Image Figure 5. Global Tourette Syndrome Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Tourette Syndrome Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Tourette Syndrome Drug Sales (2021-2032) & (k units) Figure 8. Global Tourette Syndrome Drug Average Price (US$/unit) & (2021-2032) Figure 9. Ecopipam Hydrochloride Product Image Figure 10. Dutetrabenazine ER Product Image Figure 11. CPP-115 Product Image Figure 12. AZD-5213 Product Image Figure 13. Others Product Image Figure 14. Clinic Product Image Figure 15. Hospital Product Image Figure 16. Research Center Product Image Figure 17. Others Product Image Figure 18. Global Tourette Syndrome Drug Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Tourette Syndrome Drug, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Tourette Syndrome Drug Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Tourette Syndrome Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Tourette Syndrome Drug Sales by Region in 2025 Figure 24. Global Tourette Syndrome Drug Revenue by Region in 2025 Figure 25. North America Tourette Syndrome Drug Market Size by Country in 2025 Figure 26. North America Tourette Syndrome Drug Sales Market Share by Country (2021-2032) Figure 27. North America Tourette Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 28. United States Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Tourette Syndrome Drug Market Size by Country in 2025 Figure 32. Europe Tourette Syndrome Drug Sales Market Share by Country (2021-2032) Figure 33. Europe Tourette Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 34. Germany Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific Tourette Syndrome Drug Market Size by Country in 2025 Figure 45. Asia Pacific Tourette Syndrome Drug Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific Tourette Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 47. China Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America Tourette Syndrome Drug Market Size by Country in 2025 Figure 56. South America Tourette Syndrome Drug Sales Market Share by Country (2021-2032) Figure 57. South America Tourette Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 58. Brazil Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Tourette Syndrome Drug Market Size by Country in 2025 Figure 62. Middle East and Africa Tourette Syndrome Drug Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Tourette Syndrome Drug Revenue Market Share by Country (2021-2032) Figure 64. Egypt Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Tourette Syndrome Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Tourette Syndrome Drug Sales Market Share by Type (2021-2032) Figure 70. Global Tourette Syndrome Drug Revenue Market Share by Type (2021-2032) Figure 71. Global Tourette Syndrome Drug Price (US$/unit) by Type (2021-2032) Figure 72. Global Tourette Syndrome Drug Sales Market Share by Application (2021-2032) Figure 73. Global Tourette Syndrome Drug Revenue Market Share by Application (2021-2032) Figure 74. Global Tourette Syndrome Drug Price (US$/unit) by Application (2021-2032) Figure 75. Tourette Syndrome Drug Value Chain Figure 76. Tourette Syndrome Drug Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Tourette Syndrome Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Ecopipam Hydrochloride
  • Dutetrabenazine ER
  • CPP-115
  • AZD-5213
  • Others
Applications
  • Clinic
  • Hospital
  • Research Center
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Therapix Biosciences Ltd
  • Synchroneuron Inc
  • Reviva Pharmaceuticals Inc
  • Psyadon Pharmaceuticals Inc
  • Neurocrine Biosciences Inc
  • Catalyst Pharmaceuticals Inc
  • Abide Therapeutics Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Tourette Syndrome Drug Market Size (2021-2032)
  4. 2.2.2 Global Tourette Syndrome Drug Sales (2021-2032)
  5. 2.2.3 Global Tourette Syndrome Drug Market Average Price (2021-2032)
  6. 2.3 Tourette Syndrome Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Ecopipam Hydrochloride
  9. 2.3.3 Dutetrabenazine ER
  10. 2.3.4 CPP-115
  11. 2.3.5 AZD-5213
  12. 2.3.6 Others
  13. 2.4 Tourette Syndrome Drug by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Clinic
  16. 2.4.3 Hospital
  17. 2.4.4 Research Center
  18. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Tourette Syndrome Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Tourette Syndrome Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Tourette Syndrome Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Tourette Syndrome Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Tourette Syndrome Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Tourette Syndrome Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Tourette Syndrome Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Tourette Syndrome Drug, Established Date
  9. 3.9 Global Tourette Syndrome Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva Pharmaceutical Industries Ltd
  2. 4.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 4.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 4.1.3 Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Product Portfolio
  6. 4.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 4.2 Therapix Biosciences Ltd
  8. 4.2.1 Therapix Biosciences Ltd Company Information
  9. 4.2.2 Therapix Biosciences Ltd Business Overview
  10. 4.2.3 Therapix Biosciences Ltd Tourette Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Therapix Biosciences Ltd Tourette Syndrome Drug Product Portfolio
  12. 4.2.5 Therapix Biosciences Ltd Recent Developments
  13. 4.3 Synchroneuron Inc
  14. 4.3.1 Synchroneuron Inc Company Information
  15. 4.3.2 Synchroneuron Inc Business Overview
  16. 4.3.3 Synchroneuron Inc Tourette Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Synchroneuron Inc Tourette Syndrome Drug Product Portfolio
  18. 4.3.5 Synchroneuron Inc Recent Developments
  19. 4.4 Reviva Pharmaceuticals Inc
  20. 4.4.1 Reviva Pharmaceuticals Inc Company Information
  21. 4.4.2 Reviva Pharmaceuticals Inc Business Overview
  22. 4.4.3 Reviva Pharmaceuticals Inc Tourette Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Reviva Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio
  24. 4.4.5 Reviva Pharmaceuticals Inc Recent Developments
  25. 4.5 Psyadon Pharmaceuticals Inc
  26. 4.5.1 Psyadon Pharmaceuticals Inc Company Information
  27. 4.5.2 Psyadon Pharmaceuticals Inc Business Overview
  28. 4.5.3 Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio
  30. 4.5.5 Psyadon Pharmaceuticals Inc Recent Developments
  31. 4.6 Neurocrine Biosciences Inc
  32. 4.6.1 Neurocrine Biosciences Inc Company Information
  33. 4.6.2 Neurocrine Biosciences Inc Business Overview
  34. 4.6.3 Neurocrine Biosciences Inc Tourette Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Neurocrine Biosciences Inc Tourette Syndrome Drug Product Portfolio
  36. 4.6.5 Neurocrine Biosciences Inc Recent Developments
  37. 4.7 Catalyst Pharmaceuticals Inc
  38. 4.7.1 Catalyst Pharmaceuticals Inc Company Information
  39. 4.7.2 Catalyst Pharmaceuticals Inc Business Overview
  40. 4.7.3 Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Product Portfolio
  42. 4.7.5 Catalyst Pharmaceuticals Inc Recent Developments
  43. 4.8 Abide Therapeutics Inc
  44. 4.8.1 Abide Therapeutics Inc Company Information
  45. 4.8.2 Abide Therapeutics Inc Business Overview
  46. 4.8.3 Abide Therapeutics Inc Tourette Syndrome Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Abide Therapeutics Inc Tourette Syndrome Drug Product Portfolio
  48. 4.8.5 Abide Therapeutics Inc Recent Developments
5 Global Tourette Syndrome Drug Market Scenario by Region
  1. 5.1 Global Tourette Syndrome Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Tourette Syndrome Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Tourette Syndrome Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Tourette Syndrome Drug Sales by Region: 2027-2032
  5. 5.3 Global Tourette Syndrome Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Tourette Syndrome Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Tourette Syndrome Drug Revenue by Region: 2027-2032
  8. 5.4 North America Tourette Syndrome Drug Market Facts & Figures by Country
  9. 5.4.1 North America Tourette Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Tourette Syndrome Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Tourette Syndrome Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Tourette Syndrome Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Tourette Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Tourette Syndrome Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Tourette Syndrome Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Tourette Syndrome Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Tourette Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Tourette Syndrome Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Tourette Syndrome Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Tourette Syndrome Drug Market Facts & Figures by Country
  41. 5.7.1 South America Tourette Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Tourette Syndrome Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Tourette Syndrome Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Tourette Syndrome Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Tourette Syndrome Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Tourette Syndrome Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Tourette Syndrome Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Tourette Syndrome Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Tourette Syndrome Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Tourette Syndrome Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Tourette Syndrome Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Tourette Syndrome Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Tourette Syndrome Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Tourette Syndrome Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Tourette Syndrome Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Tourette Syndrome Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Tourette Syndrome Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Tourette Syndrome Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Tourette Syndrome Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Tourette Syndrome Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Tourette Syndrome Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Tourette Syndrome Drug Value Chain Analysis
  2. 8.1.1 Tourette Syndrome Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Tourette Syndrome Drug Production Mode & Process
  5. 8.2 Tourette Syndrome Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Tourette Syndrome Drug Distributors
  8. 8.2.3 Tourette Syndrome Drug Customers
9 Global Tourette Syndrome Drug Analyzing Market Dynamics
  1. 9.1 Tourette Syndrome Drug Industry Trends
  2. 9.2 Tourette Syndrome Drug Industry Drivers
  3. 9.3 Tourette Syndrome Drug Industry Opportunities and Challenges
  4. 9.4 Tourette Syndrome Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst